Eli Lilly and Company (BMV:LLY)

Market Cap	16.46T
Revenue (ttm)	1.09T
Net Income (ttm)	337.72B
Shares Out	n/a
EPS (ttm)	374.95
PE Ratio	48.74
Forward PE	32.00
Dividend	115.58 (0.63%)
Ex-Dividend Date	Nov 14, 2025

Volume	237
Average Volume	799
Open	18,071
Previous Close	18,459
Day's Range	18,071 - 18,421
52-Week Range	11,630 - 20,340
Beta	0.39
RSI	52.95
Earnings Date	Feb 6, 2026

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD